ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GMDA Gamida Cell Ltd

0.3784
0.0126 (3.44%)
Feb 29 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 843,223
Bid Price 0.3601
Ask Price 0.3784
News -
Day High 0.379

Low
0.2184

52 Week Range

High
2.51

Day Low 0.35
Company Name Stock Ticker Symbol Market Type
Gamida Cell Ltd GMDA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0126 3.44% 0.3784 18:50:06
Open Price Low Price High Price Close Price Prev Close
0.379 0.35 0.379 0.3596 0.3658
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,102 843,223 $ 0.3650203 $ 307,794 - 0.2184 - 2.51
Last Trade Time Type Quantity Stock Price Currency
19:59:52 10 $ 0.3689 USD

Gamida Cell Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
47.75M 132.64M - 0 -79.38M -0.60 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Gamida Cell News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No GMDA Message Board. Create One! See More Posts on GMDA Message Board See More Message Board Posts

Historical GMDA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.380.3890.32020.36066572,164,151-0.0016-0.42%
1 Month0.4020.4310.3130.37004272,151,928-0.0236-5.87%
3 Months0.31280.4870.240.35340583,198,3990.065620.97%
6 Months1.231.260.21840.42932462,397,855-0.8516-69.24%
1 Year1.442.510.21841.102,918,252-1.06-73.72%
3 Years9.5610.240.21841.721,352,807-9.18-96.04%
5 Years12.9315.000.21842.44911,688-12.55-97.07%

Gamida Cell Description

Gamida Cell Ltd is a biopharmaceutical company involved in developing advanced cell therapies with the potential to cure cancer and rare, serious hematologic diseases. The company's product includes NiCord that is a cell therapy based on NAM-expanded cord blood designed to enhance and expand the life-saving benefits of hematopoietic stem cell transplant. It is also developing GDA-201 which is innate immunotherapy of expanded natural killer cells, for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma. It is developing a diverse pipeline of cell therapies using its proprietary NAM technology that has the potential to bring life-saving treatment options to patients.

Your Recent History

Delayed Upgrade Clock